carmot

Carmot Therapeutics bags $15M for GLP-1R/GIPR agonist

Carmot Therapeutics bags $15M for GLP-1R/GIPR agonist

This will take Carmot's lead Type 2 diabetes drug through clinical proof of concept.

Carmot and Amgen to identify new therapeutics for Parkinson’s

Carmot and Amgen to identify new therapeutics for Parkinson’s

The firms will leverage Carmot’s Chemotype Evolution lead-identification technology.